Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) was the recipient of a significant increase in short interest in June. As of June 15th, there was short interest totaling 10,679 shares, an increase of 597.5% from the May 31st total of 1,531 shares. Based on an average daily volume of 28,955 shares, the short-interest ratio is presently 0.4 days.
Defence Therapeutics Price Performance
Shares of OTCMKTS DTCFF traded down $0.01 during trading on Friday, hitting $0.35. 1,800 shares of the company traded hands, compared to its average volume of 8,329. Defence Therapeutics has a fifty-two week low of $0.31 and a fifty-two week high of $0.78. The business’s fifty day moving average is $0.38 and its 200 day moving average is $0.44.
About Defence Therapeutics
Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.
Featured Articles
- Five stocks we like better than Defence Therapeutics
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
